Regeneron has found success treating rare disorders, but the stock has been humbled by recent declines. Can the company get its groove back? Jim Cramer asked the CEO.
» Subscribe to CNBC: [ Ссылка ]
» Watch more Mad Money here: [ Ссылка ]
» Read more about Regeneron here: [ Ссылка ]
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: [ Ссылка ]
Watch full episodes: [ Ссылка ]
Follow Mad Money on Twitter: [ Ссылка ]
Like Mad Money on Facebook: [ Ссылка ]
Follow Cramer on Twitter: [ Ссылка ]
Connect with CNBC News Online!
Visit CNBC.com: [ Ссылка ]
Find CNBC News on Facebook: [ Ссылка ]
Follow CNBC News on Twitter: [ Ссылка ]
Follow CNBC News on Google+: [ Ссылка ]
Follow CNBC News on Instagram: [ Ссылка ]
Regeneron Pharmaceuticals CEO: Changing Medicine | Mad Money | CNBC
